Heavy Metal Toxicology and Arsenic-Based Leukemia Therapy
This community investigates the biological mechanisms of heavy metal exposure—specifically cadmium, arsenic, and lead—and the clinical application of arsenic trioxide for treating acute promyelocytic leukemia.
The research focuses on how cadmium, arsenic, and lead induce oxidative stress, DNA methylation changes, and cellular damage in models ranging from Wistar rats to human cell lines. A distinct strand of work examines the therapeutic use of arsenic trioxide in acute promyelocytic and myeloid leukemia, analyzing signaling pathways and treatment resistance. Additional studies assess the health risks associated with heavy metals in drinking water and the gut microbiota, while others explore the protective effects of antioxidants against cadmium-induced toxicity.
The largest share of the community's output is found in cadmium research, accounting for 15.6% of all cadmium research tracked, with 14,291 papers in this group. Arsenic research follows, representing 14.3% of all arsenium research with 11,978 papers, while lead research comprises 3.4% of lead research with 5,150 papers.
The community comprises 50,458 papers, published most frequently in Biological Trace Element Research, Toxicology and Applied Pharmacology, and Environmental Health Perspectives.
Recent work continues to examine the mechanisms of lead toxicity in living organisms and the immune-epigenetic effects of environmental pollutants, including transgenerational impacts. Other recent studies address the diagnosis and management of acute myeloid leukemia in pediatric patients and the role of pollutants in insulin resistance.